Last update Sept. 19, 2016
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Fesoterodine is also known as
Fesoterodine in other languages or writings:
Fesoterodine belongs to this group or family:
Main tradenames from several countries containing Fesoterodine in its composition:
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Antimuscarinic agent with atropine-like action. It is metabolized in Tolterodine
At latest update no published data on excretion into breast milk were found.
Until more published data on this drug in relation to breastfeeding is available, a known safer alternative as Tolterodine should be preferred with more favorable pharmacokinetics characteristics for lactation (e.g. high protein-binding capacity, faster elimination and lower oral bioavailability), particularly during the neonatal period and prematurity case.
Take as smallest dose as possible and avoid long-term use since anticholinergics can reduce milk production.
Monitoring anticholinergic symptoms in infants (dry mouth, constipation ..) is warranted.